IndustryCompany release

Incyte raises 2026 sales guidance as third-quarter revenue rises 14% to $1.56bn

🇺🇸 Incyte Corp (INCY) · Thu 29 Oct 2026

The US biopharma company reported strong third-quarter growth led by Opzelura and its haematology/oncology portfolio, and lifted full-year net sales guidance for several categories.

Incyte reported third-quarter 2026 results on 29 October, with total revenue of $1.56bn and net sales of $1.32bn. Both measures were up 14%.

Growth was uneven across the portfolio. Jakafi sales rose 4%, while Opzelura sales increased 36%. Haematology/Oncology sales grew 38%.

On the back of these results, the company raised its full-year 2026 net sales guidance for Opzelura, for Haematology/Oncology and for total net sales. The summary available does not give the revised guidance ranges.

Incyte also noted positive interactions with the US Food and Drug Administration at the end-of-Phase 2 stage for INCA033989. It further said that a US approval of Monjuvi in newly diagnosed diffuse large B-cell lymphoma (DLBCL) could come in the first quarter of 2027.

What it means for your team

  • Opzelura and the haematology/oncology portfolio are driving growth, while Jakafi is expanding far more slowly.
  • Positive end-of-Phase 2 feedback from the FDA on INCA033989 points to the programme moving towards later-stage development; details were not provided in the available material.
  • Market-access and regulatory teams should watch for a possible US decision on Monjuvi in newly diagnosed DLBCL in the first quarter of 2027, which would extend its use to an earlier line of treatment.

Company's press release (SEC filing): Incyte Corp ↗

Article written by VigiEye from the official source (Incyte Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →